VGL101-01.002: A Natural History Study of Patients with Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)

Vigil Neuroscience is developing an investigational drug, VGL101, for the treatment of patients with ALSP. There is no investigational drug in this study, but this natural history study will provide information that will help with the development of future treatments for ALSP, including VGL101.

The main purpose of the study is to learn more about how ALSP occurs and how the disease affects patients over time. Study participants will continue their standard of care treatment during the study.

Your participation in the study would last approximately 25 months and would include approximately 5 study visits to the study site. You will have the option to receive VGL101 in a separate study after participating in this clinical trial.

During the study, blood samples will be collected, along with MRI images, and performance and cognitive assessments and questionnaires.

To participate in this study, you will need to meet the following main entry criteria*:

1. ≥ 18 years of age
2. Diagnosed with ALSP (adult-onset leukoencephalopathy with axonal spheroids and pigmented glia)
3. Gene mutation in the CSF1R gene

*Other inclusion or exclusion criteria may apply.

Travel and stipends for participation may be available.

If you are interested in participating or for more information, please contact: trials@vigilneuro.com